Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CUTISS AG

Home Clinical Trial Sponsors and OrganizationsCUTISS AG

CUTISS AG

ACTIVE

Grabenstrasse 11, Schlieren, Zürich, Switzerlandcutiss.swissHolding11–50 employeesEstablished: 2017-03-08

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

14

6 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2017

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

8

57.1%

Phase 1

4

28.6%

Phase 3

2

14.3%

Trial Status Distribution

Active, not recruiting

5

35.7%

Completed

2

14.3%

Not yet recruiting

1

7.1%

Recruiting

6

42.9%

Clinical Trials

Trials sponsored by this organization (14)

Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

Dec 202470 participants

A multicentre, intra-patient randomised controlled Phase III study to confirm the efficacy and safety of denovoSkin™, a bilayer engineered collagen-based skin graft composed of autologous fibroblasts and keratinocytes, for the treatment of patients with deep partial and full-thickness burns

Active, not recruiting

Mar 2024108 participants

A study performed in more hospitals, to assess the safety and efficacy of a skin model that is engineered in the lab with cells of the patient (EHSG-KF) to use in treatment of full thickness burns in adults and children and compare this to the treatment with the own skin system called STSG.

Active, not recruiting

Apr 201820 participants

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children

Feb 201821 participants

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents

Oct 201714 participants

Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children

Active, not recruiting

Oct 201712 participants

A study performed in more hospitals, to assess the safety and efficacy of a skin model that is engineered in the lab with cells of the patient (EHSG-KF) to use in treatment of partial deep dermal and full thickness burns in children and compare this to the treatment with the own skin system called STSG.

Active, not recruiting

Sep 201712 participants

A study to check if the use of a skin model engeneered in the laboratory by using your own skin cells (EHSG-KF), is safe and effective to treat partial deep dermal and full thickness burns in adults and adolescents in comparison to the standard treatment used in current medicine (STSG).

Active, not recruiting

Sep 201712 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials14
Approvals
News

Back to Organizations